Cargando…
Multisystem Inflammatory Syndrome in an Adult (MIS-A) Successfully Treated with Anakinra and Glucocorticoids
During the current SARS-CoV-2 pandemic, a novel syndrome termed “multisystem inflammatory syndrome in children” (MIS-C) has emerged. MIS-C was linked to COVID-19 and shared some features with Kawasaki disease and Toxic Shock Syndrome, with a common pathogenetic substrate of hyperinflammation and cyt...
Autores principales: | Cattaneo, Paolo, Volpe, Alessandro, Cardellino, Chiara Simona, Riccardi, Niccolò, Bertoli, Giulia, Ursini, Tamara, Ustalli, Arjola, Lodi, Giovanni, Daroui, Ivan, Angheben, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305807/ https://www.ncbi.nlm.nih.gov/pubmed/34203277 http://dx.doi.org/10.3390/microorganisms9071393 |
Ejemplares similares
-
Anakinra in Refractory Multisystem Inflammatory Syndrome in Children (MIS-C)
por: Bhat, Chandrika S., et al.
Publicado: (2021) -
Anakinra treatment in multisystemic inflammatory syndrome in children (MIS-C) associated with COVID-19
por: Çaǧlayan, Şengül, et al.
Publicado: (2022) -
The Role of Glucocorticoids in the Treatment of Multisystem Inflammatory Syndrome (MIS-C)—Data from POLISH MIS-C Registry
por: Gowin, Ewelina, et al.
Publicado: (2022) -
Efficacy of anakinra on rebound of multisystem inflammatory syndrome
por: Brisca, Giacomo, et al.
Publicado: (2022) -
Use of Continuous Intravenous Anakinra Infusion in Multisystem Inflammatory Syndrome in Children
por: Alolayan, Abdulaziz, et al.
Publicado: (2023)